|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM331603829 |
| 003 |
DE-627 |
| 005 |
20250302134328.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2021.108871
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1105.xml
|
| 035 |
|
|
|a (DE-627)NLM331603829
|
| 035 |
|
|
|a (NLM)34619377
|
| 035 |
|
|
|a (PII)S1521-6616(21)00208-4
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Barnes, Thomas W
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 30.11.2021
|
| 500 |
|
|
|a Date Revised 28.03.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Despite the burgeoning field of coronavirus disease-19 (COVID-19) research, the persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibodies remains unclear. This study validated two high-throughput immunological methods for use as surrogate live virus neutralisation assays and employed them to examine the half-life of SARS-CoV-2 neutralising antibodies in convalescent plasma donations made by 42 repeat donors between April and September 2020. SARS-CoV-2 neutralising antibody titres decreased over time but typically remained above the methods' diagnostic cut-offs. Using this longitudinal data, the average half-life of SARS-CoV-2 neutralising antibodies was determined to be 20.4 days. SARS-CoV-2 neutralising antibody titres appear to persist in the majority of donors for several months. Whether these titres confer protection against re-infection requires further study and is of particular relevance as COVID-19 vaccines become widely available
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a COVID-19
|
| 650 |
|
4 |
|a Convalescent donor
|
| 650 |
|
4 |
|a Half-life
|
| 650 |
|
4 |
|a Neutralising antibodies
|
| 650 |
|
4 |
|a SARS-CoV-2
|
| 650 |
|
7 |
|a Antibodies, Neutralizing
|2 NLM
|
| 650 |
|
7 |
|a Antibodies, Viral
|2 NLM
|
| 700 |
1 |
|
|a Schulte-Pelkum, Johannes
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Steller, Laura
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Filchtinski, Daniel
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jenness, Robin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Williams, Michelle R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kober, Christina
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Manni, Sandro
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hauser, Thomas
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hahn, Aaron
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kalina, Uwe
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Simon, Toby L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Schuetz, Patrick
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Roth, Nathan J
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 232(2021) vom: 03. Nov., Seite 108871
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:232
|g year:2021
|g day:03
|g month:11
|g pages:108871
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2021.108871
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 232
|j 2021
|b 03
|c 11
|h 108871
|